To optimize the lead compound of the UW series for Chagas disease
current phase of drug development
updated 1 Jun 2021
New candidates are needed to fill the pipeline for Chagas disease treatments. The UW series is a novel series of T. cruzi inhibitors based on a 2-aryl benzothiazole scaffold identified by Fred Buckner and his group at University of Washington. The lead compound, 45DAP076, is one of the very few compounds that provides single compound cure in an in vivo model of chronic Chagas disease up to 180 days after infection. A set of additional compounds based on the closely related scaffold are being prepared to further improve the efficacy and remove concerns associated with the lead compound.
Get our latest news, personal stories, research articles, and job opportunities.